AIMS: brain metastasis is a common cause of mortality in cancer patients, and associated with poor prognosis. Our objective was to develop a clinically relevant animal model by transplanting human biopsy spheroids derived from metastatic lesions into brains of immunodeficient rats. METHODS: nine different patient brain metastases from four different primary cancers were implanted into brains of immunodeficient rats. The xenografts were compared with patient tumours by magnetic resonance imaging, histochemistry, immunohistochemistry and DNA copy number analysis. RESULTS: after transplantation, tumour growth was achieved in seven out of nine human brain metastases. Spheroids derived from four of the metastases initiated in the rat brains were further serially transplanted into new animals and a 100% tumour take was observed during second passage. Three of the biopsies were implanted subcutaneously, where no tumour take was observed. The animal brain metastases exhibited similar radiological features as observed clinically. Histological comparisons between the primary tumours from the patients, the patient brain metastases and the derived xenografts showed striking similarities in histology and growth patterns. Also, immunohistochemistry showed a strong marker expression similarity between the patient tumours and the corresponding xenografts. DNA copy number analysis between the brain metastases, and the corresponding xenografts revealed strong similarities in gains and losses of chromosomal content. CONCLUSION: we have developed a representative in vivo model for studying the growth of human metastatic brain cancers. The model described represents an important tool to assess responses to new treatment modalities and for studying mechanisms behind metastatic growth in the central nervous system.
AIMS: brain metastasis is a common cause of mortality in cancerpatients, and associated with poor prognosis. Our objective was to develop a clinically relevant animal model by transplanting human biopsy spheroids derived from metastatic lesions into brains of immunodeficientrats. METHODS: nine different patient brain metastases from four different primary cancers were implanted into brains of immunodeficientrats. The xenografts were compared with patienttumours by magnetic resonance imaging, histochemistry, immunohistochemistry and DNA copy number analysis. RESULTS: after transplantation, tumour growth was achieved in seven out of nine human brain metastases. Spheroids derived from four of the metastases initiated in the rat brains were further serially transplanted into new animals and a 100% tumour take was observed during second passage. Three of the biopsies were implanted subcutaneously, where no tumour take was observed. The animal brain metastases exhibited similar radiological features as observed clinically. Histological comparisons between the primary tumours from the patients, the patient brain metastases and the derived xenografts showed striking similarities in histology and growth patterns. Also, immunohistochemistry showed a strong marker expression similarity between the patienttumours and the corresponding xenografts. DNA copy number analysis between the brain metastases, and the corresponding xenografts revealed strong similarities in gains and losses of chromosomal content. CONCLUSION: we have developed a representative in vivo model for studying the growth of human metastatic brain cancers. The model described represents an important tool to assess responses to new treatment modalities and for studying mechanisms behind metastatic growth in the central nervous system.
Authors: Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt Journal: Neuro Oncol Date: 2015-05 Impact factor: 12.300
Authors: Azadeh Kheirolomoom; Elizabeth S Ingham; Joel Commisso; Neveen Abushaban; Katherine W Ferrara Journal: J Control Release Date: 2016-10-13 Impact factor: 9.776
Authors: Frits Thorsen; Brett Fite; Lisa M Mahakian; Jai W Seo; Shengping Qin; Victoria Harrison; Sarah Johnson; Elizabeth Ingham; Charles Caskey; Terje Sundstrøm; Thomas J Meade; Patrick N Harter; Kai Ove Skaftnesmo; Katherine W Ferrara Journal: J Control Release Date: 2013-10-29 Impact factor: 9.776
Authors: Manuel Valiente; Amanda E D Van Swearingen; Carey K Anders; Amos Bairoch; Adrienne Boire; Paula D Bos; Diana M Cittelly; Neta Erez; Gino B Ferraro; Dai Fukumura; Brunilde Gril; Meenhard Herlyn; Sheri L Holmen; Rakesh K Jain; Johanna A Joyce; Mihaela Lorger; Joan Massague; Josh Neman; Nicola R Sibson; Patricia S Steeg; Frits Thorsen; Leonie S Young; Damir Varešlija; Adina Vultur; Frances Weis-Garcia; Frank Winkler Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: Cedric Tehranian; Laura Fankhauser; Patrick N Harter; Colin D H Ratcliffe; Pia S Zeiner; Julia M Messmer; Dirk C Hoffmann; Katharina Frey; Dana Westphal; Michael W Ronellenfitsch; Erik Sahai; Wolfgang Wick; Matthia A Karreman; Frank Winkler Journal: Neuro Oncol Date: 2022-02-01 Impact factor: 12.300
Authors: Krishna M Talasila; Anke Soentgerath; Philipp Euskirchen; Gro V Rosland; Jian Wang; Peter C Huszthy; Lars Prestegarden; Kai Ove Skaftnesmo; Per Øystein Sakariassen; Eskil Eskilsson; Daniel Stieber; Olivier Keunen; Narve Brekka; Ingrid Moen; Janice M Nigro; Olav K Vintermyr; Morten Lund-Johansen; Simone Niclou; Sverre J Mørk; Per Oyvind Enger; Rolf Bjerkvig; Hrvoje Miletic Journal: Acta Neuropathol Date: 2013-02-22 Impact factor: 17.088
Authors: B-W Xie; D Park; E R Van Beek; V Blankevoort; Y Orabi; I Que; E L Kaijzel; A Chan; P J Hogg; C W G M Löwik Journal: Cell Death Dis Date: 2013-01-24 Impact factor: 8.469